# The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct04654390` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04654390](<https://clinicaltrials.gov/study/NCT04654390>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04654390

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

## Technical summary

Registry record NCT04654390. Randomized; double masking; primary purpose treatment. Start 2020-12-30 (actual); primary completion 2021-12-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 270 participants (enrolled count; ClinicalTrials.gov record NCT04654390, source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)
- Started: 2020-12-30 (actual) (ClinicalTrials.gov record NCT04654390, source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)
- Primary completion: 2021-12-17 (actual) (ClinicalTrials.gov record NCT04654390, source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)
- Completion: 2021-12-17 (actual) (ClinicalTrials.gov record NCT04654390, source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04654390, source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04654390-2022-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes Mellitus
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): DWP16001 Amg
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: b78a82cbd7b07907151e7df083fc2d6aa8503044b0672f33ba3f54ab105d772e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
